Avexitide, a novel GLP-1 receptor antagonist, reduces hypoglycemic events in patients with post-bariatric hypoglycemia (PBH), according to findings from the LUCIDITY trial reported at ObesityWeek, the Obesity Society’s annual meeting.
Through 16 weeks, the mean weekly rate of level 2 and 3 hypoglycemic events, the primary endpoint, was 0.55 with avexitide and 1.24 with placebo, a 55% relative reduction (rate ratio 0.45; 95% CI 0.32-0.63), with consistent results across subgroups and sensitivity analyses.
Side effects, primarily gastrointestinal or related to the injection site, were typically of mild to moderate intensity.
PBH is characterized by recurrent hypoglycemia usually occurring 1 to 3 hours after meals, “and we think that a key driver . . . is this exaggerated GLP-1 response, which then leads to hyperinsulinemic hypoglycemia,” said presenter Marilyn Tan, MD, a clinical professor of medicine at the Stanford University School of Medicine, CA.
The prevalence of PBH requiring ongoing medical management is unclear but is estimated to be about 12% after Roux-en-Y gastric bypass (RYGB) and 5% after vertical sleeve gastrectomy.
No dedicated treatments exist, and medical nutrition therapy combining complex, low-glycemic-index carbs with fat and protein is the mainstay. But breakthrough hypoglycemia remains common, Dr. Tan told Doximity. “The diet is very restrictive and, even if someone can follow it, it ends up altering their quality of life.”
Prior studies have shown that avexitide reduces hypoglycemia by dampening the postprandial insulin response. The drug was further evaluated in the multicenter LUCIDITY trial, which included 78 patients (mean age 50.8 years; 96% women) diagnosed with PBH after RYGB. On average, patients had lived with PBH for more than 5 years, with 68% reporting daily symptoms and 47% a history of losing consciousness.
After a 21-day run-in period, patients were randomized 3:2 to subcutaneous avexitide 90 mg once daily or placebo for 16 weeks, on top of dietary management.
The primary efficacy endpoint, combining weekly level 2 hypoglycemic events (glucose <54 mg/dL) confirmed by self-monitored blood glucose and independently adjudicated level 3 events involving altered mental and/or physical function requiring assistance, was reduced with avexitide.
Hypoglycemic events declined from baseline by 72.9% with avexitide and 37.8% with placebo (P =0.000034). Dr. Tan attributed the strong placebo response to the use of gold-standard medical nutrition therapy and glucose-monitoring tools, along with regular check-ins.
Treatment-emergent adverse events (TEAEs) occurred in 83% of avexitide-treated patients and 63% of those receiving placebo, although only one patient in each group discontinued treatment due to an event deemed related to study drug.
The most common AE was diarrhea (34% with avexitide and 10% with placebo), followed by injection-site erythema, bruising, and pain. These events were generally mild to moderate and often resolved while treatment continued, Dr. Tan said. She added that patients she enrolled found “the therapeutic effects of the avexitide to outweigh any mostly transient side effects.”
There were no clinically meaningful changes in body weight or fasting plasma glucose.
After the randomized phase, most patients entered a 32-week open-label extension and some have since moved into an expanded access program.
Avexitide has not been approved by the FDA, but “if it does become approved, [it] really would provide a lifeline for these patients,” improving their safety and leading to, “hopefully, restoration of some more normal quality of life,” Dr. Tan said.



